Table 1 Immune-related adverse events occurred during treatment with immune-checkpoint inhibitors.
Pt ID | irAE | Drug(s) | Grade | Action (ICI) | Outcome |
|---|---|---|---|---|---|
#1 | Thyrotoxicosis | Pembrolizumab | 1 | None | Resolved |
#1 | Hypothyroidism | Pembrolizumab | 2 | None | Controlled with drugs |
#2 | Acute renal failure | Pembrolizumab | 3 | Permanent suspension | Resolved |
#2 | Interstitial pneumonia | Pembrolizumab | 1 | Permanent suspension | Resolved |
#3 | Immune fever | Tislelizumab | 1 | None | Resolved |
#4 | Pancreatitis | Nivolumab (+ BV) | 3 | Permanent suspension of BV | Resolved |
#4 | Diabetes mellitus | Nivolumab (+ BV) | 2 | None | Controlled with drugs |
#4 | Thyrotoxicosis | Nivolumab (+ BV) | 1 | None | Resolved |
#4 | Hypothyroidism | Nivolumab (+ BV) | 2 | None | Resolved |
#5 | Hypothyroidism | Nivolumab (+ BV) | 2 | None | Resolved |
#6 | Acute hepatitis | Nivolumab (+ BV) | 2 | Permanent suspension | Resolved |
#7 | Hypersensitivity pneumonia | Nivolumab (+ BV) | 1 | None | Resolved |
#8 | Muscle pain | Nivolumab (+ BV) | 1 | Temporary interruption | Resolved |
#9 | Thyrotoxicosis | Pembrolizumab | 1 | None | Resolved |
#9 | Hypothyroidism | Pembrolizumab | 2 | None | Resolved |
#9 | Diffuse pain in the major joints | Nivolumab (+ BV) | 2 | None | Resolved |
#10 | Hypothyroidism | Nivolumab (+ BV) | 2 | None | Resolved |
